Intellia Therapeutics’ (NASDAQ:NTLA) “Buy” Rating Reiterated at Jefferies Group LLC

Jefferies Group LLC reissued their buy rating on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a research report report published on Saturday, July 22nd. They currently have a $36.00 price target on the stock.

Other equities analysts also recently issued research reports about the company. Oppenheimer Holdings, Inc. assumed coverage on Intellia Therapeutics in a report on Tuesday, July 18th. They issued a market perform rating on the stock. TheStreet upgraded Intellia Therapeutics from a d+ rating to a c- rating in a report on Thursday, July 6th. Credit Suisse Group set a $24.00 target price on Intellia Therapeutics and gave the company a buy rating in a report on Saturday, June 3rd. Zacks Investment Research downgraded Intellia Therapeutics from a hold rating to a sell rating in a report on Thursday, April 6th. Finally, Wedbush reiterated an outperform rating and issued a $25.00 target price on shares of Intellia Therapeutics in a report on Wednesday, May 3rd. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Intellia Therapeutics presently has a consensus rating of Buy and a consensus target price of $24.83.

Intellia Therapeutics (NASDAQ:NTLA) traded down 4.35% on Friday, reaching $15.16. 334,538 shares of the company were exchanged. The stock has a 50-day moving average price of $16.46 and a 200 day moving average price of $14.44. The stock’s market capitalization is $547.46 million. Intellia Therapeutics has a 52 week low of $10.83 and a 52 week high of $24.90.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $5.83 million. The firm’s revenue was up 40.5% compared to the same quarter last year. Analysts forecast that Intellia Therapeutics will post ($1.74) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/08/19/intellia-therapeutics-nasdaqntla-buy-rating-reiterated-at-jefferies-group-llc-updated-updated-updated.html.

In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 12.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in shares of Intellia Therapeutics during the second quarter valued at approximately $101,000. Nisa Investment Advisors LLC bought a new position in shares of Intellia Therapeutics during the second quarter valued at approximately $134,000. Bank of Montreal Can increased its position in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares during the period. Nationwide Fund Advisors increased its position in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares during the period. Finally, IHT Wealth Management LLC bought a new position in shares of Intellia Therapeutics during the first quarter valued at approximately $117,000. Institutional investors own 47.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

What are top analysts saying about Intellia Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit